title: Comparison of Therapeutic G-CSF Cycles and Prophylactic G-CSF Cycles in Patients Receiving Paclitaxel and Carboplatin Combination Chemotherapy for Ovarian Cancer: A Retrospective Study Report.
abstract: OBJECTIVE
  The aim of the present study was to investigate the differences between therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylactic G-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.
  
  
  METHODS
  Medical records of 15 women who received paclitaxel and carboplatin combination chemotherapy for ovarian cancer between January 2003 and December 2012 were analyzed retrospectively. All 15 patients completed 6 cycles of paclitaxel and carboplatin as the first-line chemotherapy. The complications were compared between therapeutic G-CSF cycles and prophylactic G-CSF cycles.
  
  
  RESULTS
  The number of chemotherapy cycles correlated with the ratio of prophylactic G-CSF cycles. It was considered that earlier prophylactic G-CSF injections were chosen due to a gradual decrease in WBC and neutrophil counts. The WBC and neutrophil counts were significantly higher in prophylactic G-CSF cycles than in therapeutic G-CSF cycles. However, there were no significant differences in the intervals of chemotherapy, delay of chemotherapy, and incidence of febrile neutropenia between the therapeutic G-CSF and prophylactic G-CSF cycles.
  
  
  CONCLUSIONS
  Prophylactic G-CSF injections were not effective in preventing the incidence of febrile neutropenia in patients receiving paclitaxel and carboplatin combination chemotherapy for ovarian cancer.
authors: Department of Obstetrics and Gynecology, JA Kochi Hospital, Japan.
authors: Masaaki
authors: M
authors: Kawashima
authors: Department of Obstetrics and Gynecology, JA Kochi Hospital, Japan.
authors: Hajime
authors: H
authors: Kondo
keywords: granulocyte-colony stimulating factor (G-CSF); ovarian cancer; paclitaxel and carboplatin combination chemotherapy
references: Clin Infect Dis. 2011 Feb 15;52(4):e56-93
references: 21258094
references: J Clin Oncol. 2006 Jul 1;24(19):3187-205
references: 16682719
references: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD003189
references: 18843642
references: J Clin Oncol. 2003 Sep 1;21(17):3194-200
references: 12860964
references: Lancet. 2009 Oct 17;374(9698):1331-8
references: 19767092
references: Eur J Gynaecol Oncol. 2014;35(1):48-51
references: 24654461